We presented positive data from our Phase II clinical trial of ALN-TTR02 for the treatment of transthyretin-mediated amyloidosis (ATTR) at the Biennial Meeting of the Peripheral Nerve Society being held June 29 – July 3. Interim results show that multiple doses of ALN-TTR02 led to robust and statistically significant knockdown of serum TTR protein levels of up to 93%. Knockdown of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, and durable, and similar activity was observed toward both wild-type and mutant protein. In addition, ALN-TTR02 was found to be generally safe and well tolerated in this study.
[spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ALN-TTR02-PhaseII-InterimResults-June2013.pdf" type="(0.7 MB PDF)"] View our presentation [/spotlight-link]
[spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ALN-TTR02-PhII-PNSposter-130630.pdf" type="(0.7 MB PDF)"] View our poster [/spotlight-link]
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=774605" type=" "] Read our press release[/spotlight-link]